In the unadjusted analysis, patients who received anti-CD38 mAbs had significantly better demographic and clinical characteristics, including younger age, better performance status, a lower probability of dementia, a higher G8 level, and lower ADL and IADL scores. This evidence concerns the gene CD38 and dementia.